MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/120/0.1/20.09.24 | Real-time Bid/Ask 10:23:16 2024-06-14 am EDT | ||
| 0.103 EUR / 0.113 EUR | +6.93% |
|
| Current month | +36.49% | ||
| 1 month | +134.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.093 | -7.92% |
| 24-06-13 | 0.101 | +1.00% |
| 24-06-12 | 0.1 | +4.17% |
| 24-06-11 | 0.096 | +21.52% |
| 24-06-10 | 0.079 | -4.82% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 08:22 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME1VG6 |
| ISIN | DE000ME1VG65 |
| Date issued | 2023-10-10 |
| Strike | 120 $ |
| Maturity | 2024-09-20 (98 Days) |
| Parity | 10 : 1 |
| Emission price | 0.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.191 € |
|---|---|
| Lowest since issue | 0.034 € |
| Spread | 0.01 € |
| Spread % | 8.93% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.67
USD
Average target price
96.24
USD
Spread / Average Target
+9.77%
- Stock Market
- Warrants
- Warrant
